about
Patient Mutation Directed shRNA Screen Uncovers Novel Bladder Tumor Growth Suppressors.Oncogenic HRAS Activates Epithelial-to-Mesenchymal Transition and Confers Stemness to p53-Deficient Urothelial Cells to Drive Muscle Invasion of Basal Subtype CarcinomasGON4L Drives Cancer Growth through a YY1-Androgen Receptor-CD24 Axis.Diagnostic Microdosing Approach to Study Gemcitabine Resistance.Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer.LncRNA UCA1 promotes the invasion and EMT of bladder cancer cells by regulating the miR-143/HMGB1 pathway.
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacogenomics in bladder cancer.
@en
Pharmacogenomics in bladder cancer.
@nl
type
label
Pharmacogenomics in bladder cancer.
@en
Pharmacogenomics in bladder cancer.
@nl
prefLabel
Pharmacogenomics in bladder cancer.
@en
Pharmacogenomics in bladder cancer.
@nl
P2860
P1433
P1476
Pharmacogenomics in bladder cancer.
@en
P2093
Dan Theodorescu
Garrett M Dancik
P2860
P356
10.1016/J.UROLONC.2013.09.007
P577
2014-01-01T00:00:00Z